INVO Fertility Business Summary

INVO Fertility, Inc. (NASDAQ: IVF) operates a dual-revenue business model centered on the commercialization of its proprietary INVOcell® medical device and the direct operation of specialized fertility clinics. Revenue is primarily generated through clinic-level service fees from its expanding network of INVO Centers and traditional IVF facilities—including the Wisconsin Fertility Institute and the Indiana-based Family Beginnings—supplemented by the direct sale of its FDA-cleared intravaginal culture (IVC) device to third-party practitioners. The company’s primary business segments include Clinic Operations, which focuses on providing affordable assisted reproductive technology (ART), and Product Sales, which targets the global medical device market. Positioned as a cost-disruptor in the fertility sector, INVO Fertility competes with major entities such as Progyny, Inc. (PGNY), The Cooper Companies (COO), and Femasys Inc. (FEMY), carving out a niche by offering a "natural" fertilization alternative that significantly reduces laboratory overhead and patient costs compared to conventional IVF. The leadership team is led by CEO Steven M. Shum, who possesses a deep background in corporate finance and executive management from his tenures at Eastside Distilling and XZERES Corp. Supporting the company’s aggressive expansion is Chief Business Officer Andrea Goren, an investment banking veteran with over 30 years of experience in private equity and $1 billion in transaction history, and CFO Terah Krigsvold, who was elevated from Corporate Controller in December 2025. Technical and regulatory oversight is managed by J. Chris Jensen, VP of Engineering, Quality and Regulatory Affairs, a 35-year medical device industry veteran formerly with CooperSurgical. While the company was founded to commercialize the inventions of Claude J. Edkins, its current trajectory is supported by notable institutional investors following a $7.5 million warrant inducement in early 2026 and a board that includes strategic leaders like Lyn Falconio, focusing on a "hub-and-spoke" model to scale clinical access nationwide.